TMCnet News
Big Changes for Medtech in First Half of 2015 While Pharma Set To Break RecordsThe first half of 2015 has continued to confound the naysayers of the pharma industry, with deal making, venture funding and share price indices all going strong. Meanwhile, the medtech sector is much changed from a year or even six months ago, with some of the biggest names shifting to take a larger share of the market and others moving out of it altogether. Pharma & Biotech Half-Year Review 2015 Highlights
"The big question as ever with the industry is how much is too much but so far, it looks as if 2015 will not be the year when the bottom falls out of the market," said Lisa Urquhart, EP Vantage editor and co-author of the report. "It looks for now like the sector is heading for what will hopefully be a gentle slowdown rather than a full-blown crash." The full version of the Pharma & Biotech Half-Year Review 2015 can be downloaded for free at www.evaluategroup.com/PharmaBiotechHalfYear2015. Medtech 2015 Half-Year Review Highlights
The full version of the Medtech 2015 Half-Year Review report can be downloaded for free at www.evaluategroup.com/MedtechHalfYear2015. About Evaluate Ltd. Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, uses our strategic analysis to deliver daily opinion and industry insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter (News - Alert): @evaluatepharma, @evaluatemedtech, @evaluateJP, @epclinicaltrial, @epvantage. View source version on businesswire.com: http://www.businesswire.com/news/home/20150820005085/en/ |